Arsenic trioxide induce apoptosis independent of TNFR-I and CD30 pathways in Acute promyelocytic leukemia patient with t(15;17) translocation.
,
Abstract
Arsenic trioxide (ATO) has been reported to induce apoptosis in Leukemic cells of Acute Promyelo-cytic Leukemia (APL) patients through different pathways. However, the exact mechanism of ATO-induced apoptosis is not yet clear. Co stimulation of death receptors CD30 and tumor necrosis factor receptor type one (TNFR-I) is one of the postulated mechanisms.In the present study we aimed to evaluate their involvement in fresh Promyelocytic cells separated from bone marrow of APL patients. Immunomagnetic separated cells were treated up to 48 hr at clinically tolerable concentrations of ATO (0.5-2.0 µmol/l) and expression of TNFR-I and CD30 were evaluated within the apoptotic and live populations using a sensitive triple color flow cytometric method for measuring apoptosis in combina¬tion with dual color immunofluorescence. Our results suggest that the expression of TNFR-I and CD30 might not be related to ATO-induced apoptotic cell death.
warrell RP Jr, The H, Wang Z-Y, et al. Acute pro- myelocytic leukemia. N Engl J Med. 1993;329:177-189
Grignani F, Ferrucci PF, Testa U, et al. The Acute promyelocytic leukemia-specific PML-RARα fusion pro- tein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993;74:423
Antman KH. The history of Arsenic cancer therapy. Oncologist. 2001;6:1-2
Guo-Qiang Chen, Xue-Geng Shi, Wei Tang, et al. Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL): I. As2O3 Exerts Dose-Dependent Dual Effects on APL Cells. Blood 1997;89:3345-3353
Miller WH Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002;7,1:1-13
Miller WH, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62(14):3893-3903
Li H, Zhu H, Xu Cl, et al. Cleavage of Bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501
Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 inter- acting protein, mediates cytochrom C release from mito- chondria in response to activation of cell surface death receptors. Cell 1998;94:481-490
X Cai, Y-L Shen, Q Zhu, et al. Arsenic trioxide- induced apoptosis and differentiation are associated re- spectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000;14:262-270
S-H Woo, I-C Park, M-J Park, et al.Arsenic trioxide induces apoptosis through a reactive oxygen species- dependent pathway and loss of mitochondrial membrane potential in Hela cells. Int J Oncol 2002;21:57-63
Nicholas Harper, Michelle Hughes, Marion MacFarlane, and Gerald M. Cohen. Fas-associated death domain protein and Caspase-8 are not recruited to the Tumor Necrosis Factor Receptor 1 signaling complex during Tumor Necrosis Factor-induced apoptosis. J Biol Chemis, 278(28) July 1125534-41, 2003.
Duckett CS, Thompson CB, CD30-dependent degra- dation of TRAFII implication for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. 11:2810, 1997
Flo RW, Naess A, Lund-Johansen F, Maehle BO, Sjursen H, Lehmann V, Solberg CO. Negative selection of human monocytes using magnetic particles covered by anti-lymphocyte antibodies. J Immunol Methods. 1991 Mar 1;137(1):89-94.
Schmid, I., C. H. Uittenbogaart, B. Keld, J. V. Giorgi. 1994. A rapid method for measuring apoptosis and dual- color immunofluorescence by single laser flowcytometry. J. Immunol. Methods 170:145-157
Ormerod MG, Paul F, Cheetham M, Sun XM, Dis- crimination of apoptotic thymocytes by forward light scatter.Cytometry. 1995 Nov 1;21(3):300-4
Wallach D, Varfolomeev EE, Goltsev YV, Kovalenko AV, Boldin MP: Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331-367, 1999
Sakurai, T; Kaise, T; Matsubara, C;: inorganic and mutilated arsenic compound induce cell death in murine macrophages via different mechanisms. Chem. Res. Toxicol. 11(4), 273-83,1998
Tartaglia LA, Weber RF, Figari IS, Reynolds C, Pal- ladino, MA jr, Goeddel DV: The two different receptor for tumor necrosis factor mediate distinct cellular re- sponses. Proc Natl Acad Sci USA 88:9292-96,1991
Pinckard JK, Sheehan Kcf, Schreiber Rd: Ligand- induced formation of P55 and P75 tumor necrosis factor receptor heterocompelexes on intact cells. J Biolol Chem 272:10784-89, 1997
Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Sciences 281:1305-08, 1998
Younes, Anas; Kadin, Marshal E: Emergimg applica- tion of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol, 21(18) 15 Sep, 3526-34, 2003
Ugo Testa, Fransisco Grignani, Paollo Samoggia, Cristiana Zanetti, Roberta Rccioni, Fransisco Lo coco, Danyella Diveria, Nadia Felli, Carlo Gambacorti Passerini, et al. The PML/RAR-α fusion protein inhibits tumor necrosis factor -α- induced apoptosis in U937 cells and Acute promyelocytic leukemia blasts. J. Clin. In- vest.101(10): 2278-89 1998
Schmelz K, Wieder T, Tamm I, Muller A, Essmann F, Geilen CC, Schulzeosthoff K, Dorken B, Daniel PT. Tumor necrosis factor alpha sensitizes malignant cells to chemoteraputic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. Oncogene. Sep 2;23(40):6743-59,200
| Files | ||
| Issue | Vol 2, No 1 (2005) | |
| Section | Articles | |
| Keywords | ||
| Acute Promyelocytic Leukemia Arsenic trioxide apoptosis CD30 TNFR-I | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
